Related by context. All words. (Click for frequent words.) 63 Bayer HealthCare Onyx Pharmaceuticals 61 inferential statistics 61 kidney urologic 61 nonrandomized 60 prospective multicentre 60 multicentre prospective 60 CATIE AD 60 metaanalysis 60 randomized discontinuation 60 Thalomid ® 59 Non inferiority 59 PrevOnco 59 relapsed MM 59 Temsirolimus 59 MAGE A3 ASCI 59 Randomized controlled 59 hematopoietic cancers 59 placebo controlled multicenter 59 prospective nonrandomized 59 Deutsches Arzteblatt International 59 randomized controlled multicenter 59 retrospective cohort 59 ACCORD Lipid 59 Intervention Effectiveness CATIE 58 ORAL Solo 58 Cardiotoxicity 58 noscapine 58 prospective observational studies 58 MediGene focuses 58 trastuzumab emtansine T DM1 58 confirmatory clinical 58 number NCT# ClinicalTrials.gov 58 CaPSURE 58 AVOREN 58 fight PI3K activation 58 REMINYL ® 58 surveys Herbenick 58 Intervention Effectiveness 58 recurrent metastatic ovarian cancer 58 limiting generalizability 58 clinico pathological 57 ROCKET AF 57 biologic DMARDs 57 Lou Sessinger column 57 STEP BD 57 AE# vaccine 57 CHAMPION PCI 57 EXPLORE Xa 57 Subgroup analysis 57 Proellex TM 57 multicentre randomized 57 Rigorous scientific 57 Multiple logistic regression 57 generalisability 57 atherothrombotic disease 57 Opioid induced bowel dysfunction 57 EchoCRT 57 tramiprosate Alzhemed TM 57 ONTARGET 57 landmark ATHENA 57 blinded randomized placebo controlled 57 TransVax ™ 57 staphylococcal vaccine 57 postapproval 57 Mantel Haenszel 57 Carotid Revascularization Endarterectomy vs. 57 toenail onychomycosis 57 blinded randomized 57 Vaxfectin R 57 prospectively stratified 57 fusion enhancers 57 methodological limitations 57 multicenter multinational 57 dosimetric 57 Cytolin R 57 GI motility disorders 56 Clinical Antipsychotic Trials 56 delipidation 56 MERLIN TIMI 56 Prostate AdenoCarcinoma Treatment 56 ENMD # 56 subgroup analyzes 56 ACCORD Eye 56 PREVENT IV 56 OvaRex ® MAb 56 Vaxfectin 56 ConclusionThis 56 CYT# potent vascular disrupting 56 thorough QT 56 ASTEROID 56 Multivariate logistic regression 56 Evidence Therapeutic 56 biostatistical analysis 56 Alpha Tocopherol Beta Carotene 56 CURRENT OASIS 7 56 LAB CGRP 56 phase IIIb 56 genomewide association study 56 Phase #/#a 56 BCIRG 56 ExTRACT TIMI 56 bioequivalency 56 EEG abnormalities 56 neuroblocking technology 56 volociximab 56 next generation URAT1 56 prospective randomized multicenter 56 Meta analyzes 56 mg BID dose 56 NB S# strontium malonate 56 journal Gynecologic Oncology 56 designated HVTN 56 Pre Exposure Prophylaxis 56 NAMCS 56 SORT OUT III 56 conditional logistic regression 56 empiric 56 CyPath ® 56 efficacy evaluable 56 Deforolimus 56 Val HeFT 56 SEER database 56 beta carotene supplementation 56 Stenting Trial CREST 56 clinicopathological 56 triple nucleoside 56 cerebral microbleeds 56 observational cohort 56 Myerburg 56 cyclophilin inhibitors 56 Relapsing remitting MS 56 ThermoDox ® clinical 56 multicenter randomized clinical 56 BMC Musculoskeletal Disorders 55 neuronal nicotinic receptor NNR 55 Balloon sinuplasty 55 multicenter Phase II 55 multivariable Cox 55 Zolpimist ™ 55 genotypic resistance 55 Zemplar Capsules 55 residual confounding 55 MGd 55 GCP compliant 55 retrospective cohort study 55 CCR5 receptor antagonist 55 Aeolus Pharmaceuticals Announces 55 florbetaben 55 Observational studies 55 MYTHOS trial 55 IMPROVE HF 55 ImmunoGen TAP technology 55 BRIM3 55 TLR agonists 55 RE LY 55 AVERROES 55 Glycopyrrolate 55 generalizability 55 prelicensure 55 Virtual Histology 55 chemo immunotherapy 55 follicular adenoma 55 clinicopathologic 55 aspirin clopidogrel 55 Intervention Trial GAIT 55 PSMA ADC 55 samalizumab 55 microarray gene expression 55 lung cancer NSCLC 55 methodologic 55 pivotal bioequivalence 55 Towering scholar 55 randomized controlled trials RCTs 55 pharmacokinetic pharmacodynamic PK PD 55 PLX STROKE targeting 55 NO# [002] 55 HCV SPRINT 55 ADVANCE PD 55 chemoprevention trials 55 Kurella Tamura 55 BARI 2D 55 NOD mouse 55 PROCHYMAL 55 Cardiorespiratory fitness 55 Francesca Bravi 55 Lancet Oncology journal 55 Rigel R# 55 EC Cysteamine 55 Teriflunomide 55 CCR5 inhibitor 55 SYNERGY Stent 55 Cognitive impairment 55 hydrophobic docetaxel prodrug nanoparticle 55 Angiolix 55 immunotherapeutic approaches 55 RECORD1 55 Tesmilifene 55 postmarketing adverse 55 multivariate Cox 55 AFRS TM 54 Venous thromboembolism 54 Phase IIIb study 54 CINQUIL 54 Vauthey 54 retrospective observational study 54 molecular cytogenetic 54 pharmacokinetic interactions 54 CGEMS 54 HORIZONS AMI 54 prospective longitudinal 54 RE LY ® 54 PROSTVAC TM 54 STRIDE PD 54 antiangiogenic agent 54 deCODE AF TM 54 preclinical efficacy 54 recurrent malignant glioma 54 Subgroup analyzes 54 BEXXAR Therapeutic Regimen 54 Xelox 54 TCF#L# gene 54 causal inference 54 OMEGA Stent 54 BRAF inhibitor 54 novel VDA molecule 54 dose escalation phase 54 Islet transplantation 54 BioMAP ® 54 evaluating mipomersen 54 Vaxfectin TM 54 KN excels 54 RESOLUTE clinical 54 neuropathologic 54 CALGB 54 Evidence Therapeutic study 54 PI3K/Akt pathway inhibitor 54 Shelley Salpeter 54 #F FDG PET 54 AKT inhibitor 54 CURE AF 54 Rostropovich asserted 54 CARE HF 54 subcutaneous PRO 54 ACOSOG Z# 54 OncoVex 54 antiretroviral naïve 54 OLYMPIA registry 54 CB1 antagonists 54 NHAMCS 54 Systematic reviews 54 randomized multicentre 54 Arranon 54 adjuvant systemic 54 squamous cell lung cancer 54 trials RCTs 54 Sipuleucel T 54 ACTIVE W 54 postmenopausal hormone 54 ASPIRE HIGHER 54 Bayesian statistical 54 Mallinger eagled both 54 logistic regression models 54 oseltamivir resistance 54 Pertuzumab 54 Trandolapril 54 EURIDIS 54 placebo controlled clinical 54 selenium supplementation 54 ENDEAVOR clinical 54 Affymetrix arrays 54 stochastic optimization 54 efavirenz EFV 54 WEBENCH Visualizer 54 spontaneous regression 54 multicenter trials 54 Khazeni 54 taxane derivative 54 meta regression 54 multiple logistic regression 54 Gilead Viread 54 non nucleoside HCV 54 MADIT II 54 STK# gene 54 atherothrombotic 54 prospective multicenter 54 riociguat 54 FDG PET imaging 54 ICON7 54 peptide conjugated 54 p# biomarker 54 TWYNSTA 54 Multicenter Automatic Defibrillator Implantation 54 PK PD modeling 54 clevidipine 54 sargramostim 54 HYVET 54 RhuDex R 54 Shortened telomeres 54 CYPHER Stent 54 antidepressants fluoxetine 54 thalidomide Thalomid 54 bioinformatic approaches 54 CELVAPAN H#N# 54 PrevOnco ™ 53 genomic biomarker 53 vitro dissolution 53 oncologic outcomes 53 dimebon latrepirdine 53 Elena Losina 53 TBC M4 53 prospective multicenter study 53 monogenic 53 multicenter randomized controlled 53 TG MV 53 pharynx larynx 53 NSABP C 53 Cancer Incidence Mortality 53 pharmacologic stress 53 HMG CoA reductase inhibitors 53 Nissen meta analysis 53 journal Psychological Bulletin 53 Zevalin consolidation 53 MEND CABG 53 HPCGG 53 CTLA4 Ig 53 antiangiogenic agents 53 novel emulsion formulation 53 Myofascial pain 53 treatment naive genotype 53 Kaplan Meier curve 53 HepaMate 53 Uncontrolled hypertension 53 venous thromboembolic disease 53 Tumor Response 53 blinded randomized controlled 53 oral rivaroxaban 53 ADVEXIN therapy 53 Pharmacokinetic studies 53 multicentre 53 Erimos 53 novel therapeutic antibodies 53 herpes zoster vaccine 53 aldosterone antagonist 53 Novo TTF 53 teriflunomide 53 papillary renal cell carcinoma 53 anything Chachoute 53 Screening Trial DMIST 53 bazedoxifene conjugated estrogens 53 myocardial infarctions MIs 53 generalisable 53 CAMMS# 53 familial aggregation 53 methodologically rigorous 53 PRESEPT study 53 non adjuvanted vaccines 53 EGS# 53 anticancer therapeutics 53 KIF6 gene variant 53 etiologic 53 Phase Ib II 53 Neuroepidemiology 53 pegylated liposomal doxorubicin 53 Phase IIb III 53 Pharmacokinetic parameters 53 LUX Lung 53 gp# vaccine 53 antiplatelet therapies 53 BACcel 53 rosuvastatin Crestor 53 multivariate logistic regression 53 observational cohort study 53 Tamoxifen Citrate 53 Dabigatran 53 DNAwithPap TM Test 53 COMT genotype 53 renal cortical 53 mean ± SEM 53 NanoStat 53 ACCLAIM II 53 Cardiopulmonary bypass 53 GV# [001] 53 Fc gamma receptor 53 cytokine refractory 53 Warfarin Coumadin 53 developmental neurotoxicity 53 oral Janus kinase 53 MenSCs 53 NICE SUGAR 53 inactivated influenza vaccines 53 functional neuroimaging 53 PDE# inhibitors 53 CYP#A# CYP#D# 53 Gastrointestinal Stromal Tumors 53 virotherapy 53 Arch Surg 53 TMC# C# 53 Chronic Lyme disease 53 paternally inherited 53 LHRH receptor positive 53 retaspimycin 53 Sphingomab 53 ATACAND 53 mITT population 53 AIR2 Trial 53 phase IIa clinical 53 visceral metastases 53 Thyroid nodules 53 murine models 53 nonpharmacologic 53 therapeutic equivalence 53 differential gene expression 53 #-# Full Text 53 HORIZONS AMI trial 53 Ovarian Cancer Screening 53 NorStates Bank serves 53 bendamustine HCl 53 revaccinate according 53 longitudinal cohort study 53 KIF6 carriers 53 Endocrine Society #st 53 meta analytic 53 microwell plate 53 dacarbazine chemotherapy 53 myocardial ischaemia 53 microbiologically evaluable 53 endophenotypes 53 TAXUS VI 53 null responder 53 recurrent glioblastoma multiforme 53 See CLINICAL PHARMACOLOGY 53 PARTNER Trial 53 Bronchial thermoplasty 53 TGFBR1 * 6A 53 REALITY Trial 53 2 diabetes UKPDS 53 multicentric 53 BEXXAR therapeutic regimen 53 BCR ABL inhibitor 53 Tobias Kurth 53 TQT studies 53 DGAT1 inhibitors 53 periprocedural MI 53 zoledronic acid Reclast 53 mycophenolate mofetil 53 James Cerhan MD 52 peer reviewed journal NeuroReport 52 intracranial stenosis 52 Daniel Rotrosen MD 52 Lu AA# 52 BR.# 52 #beta estradiol 52 proteasome inhibitor 52 Massimo Napolitano 52 dyslipidaemia 52 transrectal ultrasound guided 52 GVAX ® 52 empirically validated 52 hypertension coronary 52 ALLHAT 52 Joshua Schier 52 ASCEND HF 52 stepwise logistic regression 52 Phase 1a clinical 52 autistic enterocolitis 52 ganetespib 52 oncological outcomes 52 Multivariable logistic regression 52 CBLC# 52 ONCONASE R 52 evaluating tivozanib 52 XIENCE V demonstrated 52 Randomized trials 52 basal bolus regimen 52 Clinical Psychology Review 52 oral antiplatelet agent 52 OncoVEX 52 genotype phenotype 52 NSABP B 52 Dr. Roehrborn 52 ongoing Phase IIIb 52 malignant pleural mesothelioma 52 epigenetic therapies 52 asymptomatic metastatic 52 Relapsing Remitting MS 52 HepaMate ™ 52 TMPRSS2 ERG fusion 52 CETP VV 52 controlled multicenter 52 pharmacodynamic markers 52 myoblast therapy 52 trastuzumab DM1 T DM1 52 neratinib 52 Cytogenetic 52 endothelin antagonist 52 antiepileptics 52 pharmacodynamic properties 52 extracolonic findings 52 APEX AMI trial 52 human Chorionic Gonadotropin 52 Clinicaltrials.gov 52 ALN VSP Phase 52 APPRAISE 52 patientswith 52 placebo controlled studies 52 Lodamin 52 Cinzia Marano 52 nonnucleoside reverse transcriptase inhibitors 52 sorafenib Nexavar 52 ILLUSTRATE 52 acetabular fractures 52 Mendelian randomization 52 genomewide 52 Sociodemographic 52 pharmacoeconomic 52 TAXUS IV 52 Anavex #-# 52 metastatic neuroendocrine tumors 52 String theory 52 Genetic predisposition 52 #q# deletion 52 susceptibility loci 52 prospective observational cohort 52 double blinded randomized 52 placebo controlled trials 52 lentiviral 52 Umbilical cord stem cells 52 Anticalins 52 psoriasis Crohn disease 52 Rh incompatibility 52 tipranavir ritonavir 52 Vaxfectin R adjuvant 52 nonhereditary 52 SynCon 52 carotid artery stenting CAS 52 d l leucovorin 52 torcetrapib atorvastatin 52 correlational 52 indications contraindications 52 Phase #b/#a 52 everolimus eluting stent 52 preclinically 52 randomized blinded 52 Laura Mauri 52 variant rs# 52 Truvada tablets 52 liposomal formulation 52 thromboembolic disease 52 Candesartan 52 Pebble Beach Calf 52 MDRD 52 Dasatinib 52 NESARC 52 intensive lipid lowering 52 1 diabetes T1D 52 Digital Mammographic Imaging 52 Estrogen Receptor 52 OvaRex MAb 52 tubulin inhibitor 52 AVONEX PEN 52 vidofludimus 52 GERD migraine headaches 52 probabilistic modeling 52 reverse vaccinology 52 APEX AMI 52 biopsychosocial 52 use neuroblocking technology 52 biopsychosocial model 52 haplotype map 52 mertansine 52 Dialysis Outcomes 52 mammographic breast density 52 NATRECOR ® 52 Swedish Mammography Cohort 52 VTEU 52 Randomised 52 neovascular diseases 52 Analytical Method 52 journal Epilepsia 52 NuroPro PD 52 Corus CAD 52 unmeasured confounders 52 SPARCL 52 Acura Buick Cadillac 52 ELBW infants 52 PRIMO CABG2 52 postoperative chemotherapy 52 tamoxifen Nolvadex ® 52 macrolide antibiotics 52 dose proportionality 52 Marc Sabatine 52 Framingham Offspring 52 clade B 52 hip resurfacing arthroplasty 52 Jack Pirozzolo 52 MADIT 52 DMIST 52 Dr. Sharonne Hayes 52 anti arrhythmic drug 52 pegylated interferon alfa 2b 52 eosinophilic pneumonia 52 doxorubicin Adriamycin 52 optical biosensors 52 CYP#C# gene 52 randomized crossover 52 univariate 52 proliferative retinopathy 52 CLORETAZINE TM VNP#M 52 ALB # 52 SCK difficulty 52 everolimus eluting stents 52 Anticalins R 52 selective estrogen receptor modulator 52 anti angiogenic therapy 52 meta analyzes 52 infantile colic 52 ICD therapy 52 XmAb# 52 immunosuppressive regimens 52 vitespen 52 multicenter prospective 52 prospective randomized controlled 52 DCVax R 52 Secondary efficacy endpoints 52 lipid lowering agents 52 percutaneous biopsy 52 pharmacokinetic PK study 52 morphometric vertebral fractures 52 ENESTnd 52 quinacrine 52 lipid lowering drugs 52 Avandia Actos 52 pharmacologic treatments 52 myelofibrosis polycythemia vera 52 Fanconi syndrome 52 NCCN guidelines 52 journal Cephalalgia 52 HIV HCV coinfected 52 FTIs 52 management biostatistical analysis 52 biologic plausibility 52 Study ARIC 52 Iris Shai 52 OHR/AVR# 52 SWOG 52 genomic microarray 52 Arch Neurol 52 Nalmefene 52 TTF therapy 52 NADiA 52 Tykerb lapatinib 52 LPA gene 52 placebo controlled dose escalation 52 pravastatin Pravachol 52 congenital hemophilia 52 pediatric bipolar disorder 52 Pancreatic neuroendocrine tumors 52 PFO migraine 52 tumor subtypes 52 Dr. Tashkin 52 fosbretabulin 52 Daptomycin 52 BENICAR HCT 52 EP #R 52 tranilast 52 TriActiv System 52 UKPDS 52 Velculescu 52 D. Curfman 52 Xanafide 52 urothelial cancer 52 bovine thrombin 52 Inhaled nitric oxide 52 eculizumab therapy 52 VALOR trial 51 cardio metabolic diseases 51 chronic prostatitis chronic 51 nonrandomized studies 51 inactivated strain 51 asymptomatic hyperuricemia 51 Prof. Rabani 51 hyperinsulinemic euglycemic clamp 51 cancer chemoprevention 51 PRIMO CABG 51 K ras mutations 51 NNRTI resistant virus 51 nonbacterial prostatitis 51 PROactive study 51 psychiatric disorders ATI 51 Amir Lerman 51 Phase IIA 51 budesonide MMX Phase III 51 subanalysis 51 IPAH 51 Fulvestrant 51 chronic myocardial ischemia 51 CIMZIA TM certolizumab pegol 51 symptomatic pulmonary embolism 51 histologies 51 Univariate 51 biomarker identification 51 bowel capsule endoscopy 51 LungSign TM 51 oligonucleotide microarrays 51 DermaVir Patch 51 HIV coinfected 51 vitamin D inadequacy 51 de novo AML 51 Rheos System 51 transgenic mouse models 51 EMPOWER TM 51 Medgadget.com 51 multitargeted 51 urodynamic 51 logistic regression analysis 51 Multicenter 51 Aplidin 51 MEVACOR 51 serum leptin 51 GH deficiency 51 pharmacokinetic characteristics 51 Eva Lonn 51 RE LY trial 51 Poisson regression 51 IIa clinical 51 Edge STudy 51 BERKELEY CA UroToday.com 51 MET amplification 51 Health Initiative Observational 51 CYP#D# genotype 51 Viral Immunotherapy platform 51 elotuzumab 51 gadobutrol 51 aircraft Gaenicke 51 dose escalation clinical 51 antiplatelet medications 51 ABSSSI 51 ACUITY trial 51 bought Glaxo Serevent 51 tolevamer 51 monoclonal antibody therapeutics 51 pertuzumab 51 Phase III randomized controlled 51 Human Mutation 51 histologic subtype 51 monoclonal antibody MAb 51 rALLy trial 51 Teasing caresses 51 AlloMap testing 51 Mermin oversees 51 ABCSG 51 strontium ranelate 51 CCX# 51 ADRB2 51 ovarian endometrial 51 Pharmacologic 51 flavopiridol 51 randomizing patients 51 Eric Boerwinkle 51 primary dysmenorrhoea 51 REG1 51 searchable printable 51 Dr. Fombonne 51 antitumour 51 dbGaP 51 pharmacokinetic equivalence 51 TRITON TIMI 51 nonmetastatic 51 ParAllele 51 sDNA 51 deCODE BreastCancer 51 rFVIIa 51 immunohistochemical 51 Cholesterol Levels SPARCL 51 histone deacetylase HDAC 51 x# microprocessor architecture 51 eprotirome 51 Safinamide 51 AIM HIGH 51 neuropsychiatric events 51 comorbid psychiatric disorders 51 radiolabeled TM# 51 viral kinetics 51 immunosuppressive therapies 51 Phase IIIb 51 cediranib 51 adjuvant therapies 51 Antibiotic resistant infections 51 simplex virus 51 vascular endothelial dysfunction 51 midstage clinical 51 precaution Wiehle 51 carotid plaque 51 DiLA2 51 valvular heart 51 Cardiac Allograft Rejection 51 confounds conventional wisdom 51 ToGA 51 pleiotropy 51 author Xiang Gao 51 Drospirenone 51 pharmacokinetic pharmacodynamic 51 PCI ExTRACT TIMI 51 mammographic breast 51 TBC# 51 Litx 51 antiplatelet drugs 51 Canvaxin 51 nanoelectronics photonics 51 PF # [002] 51 nucleotide analogue 51 FFR measurements 51 NeuroImage 51 TLR9 agonists 51 longitudinal cohort 51 Diamyd Medical Diamyd 51 Experimental Psychology General 51 occipital nerve stimulation 51 BCR ABL inhibitors 51 Iressa gefitinib 51 immunodeficiencies 51 TriGrid 51 Septin9 biomarker 51 Vunjak Novakovic 51 LEAPS TM 51 Memory Study WHIMS 51 Rando Allikmets 51 GnRH agonists 51 RCTs 51 Vertos II 51 NCT# ClinicalTrials.gov 51 lipid lowering therapy 51 genetic loci 51 bortezomib Velcade 51 phase Ib 51 silico prediction 51 Dickersin 51 CRLX# 51 Photodynamic therapy 51 drugable targets 51 familial clustering 51 squamous histology 51 CCCEH 51 relapsed myeloma 51 eribulin mesylate 51 poststroke depression 51 HER2 overexpression 51 Clinical Infectious Disease 51 plasma pharmacokinetics 51 journal CHEST 51 RhuDex 51 prostate cancer PCa 51 KRAS mutation status 51 nomograms 51 Nambu theories permeate 51 Hepatotoxicity 51 serogroup B 51 Plasmodium falciparum malaria 51 MEND CABG II 51 neuropsychological impairment 51 BEZ# 51 Evoltra ® 51 Immunotherapeutic 51 Frankfurt Dortmund Duesseldorf 51 allogeneic HSCT 51 CombAT study 51 triple nucleoside regimen 51 pretransplant 51 GFT# 51 atherosclerotic vascular disease 51 M# rationally 51 hepatitis B immunoglobulin 51 paclitaxel eluting stents 51 HMGCR 51 CEQ# 51 isotype 51 prospectively defined 51 #:#-# [035] 51 Acute Liver Failure 51 randomized controlled clinical trials 51 journal Liver Transplantation 51 Valdoxan 51 proteomics bioinformatics 51 INTERHEART study 51 WME ranking 51 George Ebers 51 Lymph node 51 HemoGenix 51 AML MDS 51 Oncotype 51 PG Parental guidance 51 BLP# 51 Electroencephalography 51 EMBO Molecular Medicine 51 Nexavar sorafenib 51 TransMID TM 51 Hypertensive adverse reactions 51 science journal Naturwissenschaften 51 enzyme immunoassay EIA 51 multigene expression test 51 asthma immunotherapeutic 51 canagliflozin 51 Anthracycline 51 APTIVUS ritonavir 51 trastuzumab DM1 51 biochemical profiling 51 scientifically invalid 51 HIF PH inhibitors 51 TLR antagonist 51 OnDose TM 51 proton MR spectroscopy 51 prostate carcinoma 51 cardiac revascularization 51 psychopharmacological 51 miRNA biomarkers 51 doxorubicin cyclophosphamide 51 CTEPH 51 bivariate 51 multicenter randomized placebo controlled 51 Tarvacin 51 familial predisposition 51 β blockers 51 G. biloba 51 receptor inhibitor 51 favorable pharmacokinetic profile 51 Vantia Therapeutics 51 C#T [002] 51 doxorubicin docetaxel 51 delafloxacin 51 nephron sparing surgery 51 MVA MUC1 IL2 51 Histologic 51 Computational biology 51 journal Pharmacotherapy 50 QTDP Program 50 Vernakalant 50 Referenced EEG ® 50 proteomic analysis 50 medicine EBM 50 Acute Decompensated Heart Failure 50 HBV vaccination 50 TPI ASM8 50 PLoS Currents 50 near infrared spectroscopic 50 oncogene addiction 50 Nature Genetics journal 50 Kristine Yaffe MD 50 erythropoietic agents 50 thromboprophylaxis 50 genetically altered mouse 50 newer antipsychotic medications 50 journal Chemical Senses 50 By Laurie Kulikowski 50 Chlamydia trachomatis infection 50 Tasigna prolongs 50 SPIRIT IV 50 hormone therapy estrogen 50 Edward Giovannucci 50 viral kinetic 50 antithrombotic therapy 50 By STEPHEN WILLIS 50 CEL SCI Phase III 50 IDH1 mutation 50 ongoing Phase 1b 50 MIST II 50 prostate cancer CaP 50 orofacial clefts 50 epidemiologic studies 50 Afatinib 50 Optimata 50 nonpharmaceutical interventions 50 myeloproliferative 50 S/GSK# 50 Bivalirudin 50 amyloid cascade 50 histologic examination 50 cardiac perfusion 50 VersaFilm 50 Cabilly patent 50 GPRD 50 Appropriateness Criteria 50 Toyota RAV4 Infiniti G# 50 demonstrated antitumor activity 50 NPM1 gene 50 non valvular atrial 50 synthetic siRNAs 50 pretargeting 50 HepDirect prodrug 50 SIMPADICO 50 RhuDex ® 50 Wactawski Wende 50 SNP rs# [002] 50 Neo Darwinian 50 APOE genotype 50 Adverse effects 50 pacemaker manufacturer Intrapace 50 deCODE Genetics Illumina Navigenics 50 Carotid endarterectomy 50 selective orally bioavailable